# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## **SCHEDULE 13D**

Under the Securities Exchange Act of 1934 (Amendment No. 9)

International Stem Cell Corporation

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

05577Y107

(CUSIP Number)

Ruslan Semechkin, President X-Master, Inc. 1 Overlook Drive, Unit 11 Amherst, New Hampshire 03031 Tel. (603) 672-7070

Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

Copy to:

Michael B. Tule
McLane, Graf, Raulerson & Middleton, Professional Association
900 Elm Street, P.O. Box 326
Manchester, New Hampshire 03105-0326
Tel. (603) 625-6464

July 24, 2013

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of  $\S\S240.13d-1(e)$ , 240.13d-1(f) or 240.13d-1(g), check the following box.  $\square$ 

Page 1 of 9

CUSIP No. 05577Y107	
1. Names of Reporting	Persons.
X-Master, Inc.	
	te Box if a Member of a Group (See Instructions)
(a) $\square$	a comp (con manufil)
(b) 🗵	
3. SEC Use Only	
4. Source of Funds (See	Instructions)
WC, OO	
	of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
E	The Legal 1 recordings is required 1 distant to terms 2(a) of 2(b)
6. Citizenship or Place of	of Organization
A New Hampshire Corp	
	7. Sole Voting Power
	8. Shared Voting Power
Number of Shares	6. Shared voting I ower
Beneficially	91,858,594 <sup>1</sup>
Owned by	9. Sole Dispositive Power
Each Reporting	71 Sold Billipositive Forter
Person With:	10. Shared Dispositive Power
	91,858,594 <sup>1</sup>
11. Aggregate Amount	Beneficially Owned by Each Reporting Person
91,858,594 <sup>1</sup>	
12 Check if the Aggreg	gate Amount in Row (11) Excludes Certain Shares (See Instructions)
£	
13. Percent of Class Re	presented by Amount in Row (11)
46.6% <sup>2</sup>	
14. Type of Reporting P	Person (See Instructions)
CO	

<sup>1</sup> Of the 91,858,594 shares of common stock, \$.001 par value ("Common Shares") reported, 8,000,000 Common Shares are held by the Reporting Person and 5,000,000 Common Shares are issuable upon conversion of 10 shares of Series D Preferred Stock issued to the Reporting Person. An additional 18,536,799 Common Shares are held by A. Semechkin and 42,710,997 Common Shares are issuable upon conversion of 33 shares of Series D Preferred Stock held by A. Semechkin, the exercise of warrants to purchase 23,246,997 Common Shares presently exercisable, and the exercise of options to purchase 2,964,000 Common Shares presently exercisable or which A. Semechkin has the right to exercise within 60 days, of which the Reporting Person may be deemed the indirect beneficial owner. 693,297 Common Shares are held by R. Semechkin, and an additional 2,667,501 Common Shares are issuable upon the exercise of warrants to purchase 2,003,001 Common Shares presently exercisable, and the exercise of options to purchase 664,500 Common Shares presently exercisable or which R. Semechkin has the right to exercise within 60 days, of which the Reporting Person may also be deemed the indirect beneficial owner. 14,250,000 Common Shares are issuable upon conversion of 5,000,000 shares of Series G Preferred Stock issued to AR Partners, LLC, of which the Reporting Person may be deemed the indirect beneficial owner.

<sup>&</sup>lt;sup>2</sup> The calculation of the percentage is based on (i) 112,363,815 Common Shares outstanding as of May 3, 2013, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, (ii) 20,000,000 Common Shares outstanding upon a sale by the Issuer on July 24, 2013, as reported by the Issuer in its Current Report on Form 8-K, and (iii) 64,628,498 Common Shares to be issued upon the conversion of 43 shares of Series D Preferred Stock, 5,000,000 shares of Series G Preferred Stock, the exercise of warrants to purchase 25,249,998 Common Shares, and the exercise of options to purchase 3,628,500 Common Shares of the Issuer.

CUSIP No. 05577Y107			
1. Names of Reporting I	Persons.		
Andrey Semechkin			
	e Box if a Member of a Group (See Instructions)		
(a) □	e box if a Memoer of a Group (see histractions)		
(b) ⊠			
3. SEC Use Only			
4. Source of Funds (See	Instructions)		
DE OO			
PF, OO  Chack if Disalegure of	of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
£	1 Legal Floceedings is Required Fulstiani to Items 2(d) of 2(e)		
6. Citizenship or Place of	f Organization		
-			
Citizen of Russia			
	7. Sole Voting Power		
	8. Shared Voting Power		
Number of Shares	o. Shared voining tower		
Beneficially	91,858,594 <sup>3</sup>		
Owned by	9. Sole Dispositive Power		
Each Reporting Person With:			
T CISON TO INI.	10. Shared Dispositive Power		
	2		
11 4	91,858,594 <sup>3</sup>		
11. Aggregate Amount	Beneficially Owned by Each Reporting Person		
91,858,594 <sup>3</sup>			
	ate Amount in Row (11) Excludes Certain Shares (See Instructions)		
£			
13. Percent of Class Re	presented by Amount in Row (11)		
46.6% 4			
14. Type of Reporting P	erson (See Instructions)		
IN			

<sup>&</sup>lt;sup>3</sup> Of the 91,858,594 Common Shares reported, 18,536,799 Common Shares are held by the Reporting Person and an additional 42,710,997 Common Shares are issuable upon conversion of 33 shares of Series D Preferred Stock held by the Reporting Person, the exercise of warrants to purchase 23,246,997 Common Shares presently exercisable, and the exercise of options to purchase 2,964,000 Common Shares presently exercisable or which the Reporting Person has the right to exercise within 60 days. 8,000,000 Common Shares are held by X-Master and 5,000,000 Common Shares are issuable upon conversion of 10 shares of Series D Preferred Stock held by X-Master, of which the Reporting Person may be deemed the indirect beneficial owner. 693,297 Common Shares are held by R. Semechkin, and an additional 2,667,501 Common Shares are issuable upon the exercise of warrants to purchase 2,003,001 Common Shares presently exercisable, and the exercise of options to purchase 664,500 Common Shares presently exercisable or which R. Semechkin has the right to exercise within 60 days, of which the Reporting Person may also be deemed the indirect beneficial owner. 14,250,000 Common Shares are issuable upon conversion of 5,000,000 shares of Series G Preferred Stock issued to AR Partners, LLC, of which the Reporting Person may be deemed the indirect beneficial owner.

<sup>&</sup>lt;sup>4</sup> The calculation of the percentage is based on (i) 112,363,815 Common Shares outstanding as of May 3, 2013, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, (ii) 20,000,000 Common Shares outstanding upon a sale by the Issuer on July 24, 2013, as reported by the Issuer in its Current Report on Form 8-K, and (iii) 64,628,498 Common Shares to be issued upon the conversion of 43 shares of Series D Preferred Stock, 5,000,000 shares of Series G Preferred Stock, the exercise of warrants to purchase 25,249,998 Common Shares, and the exercise of options to purchase 3,628,500 Common Shares of the Issuer.

CUSIP No. 05577Y107			
1. Names of Reporting I	Persons.		
Ruslan Semechkin			
2. Check the Appropriat	e Box if a Member of a Group (See Instructions)		
(a) 🗆			
(b) ⊠			
3. SEC Use Only	Teste stime)		
4. Source of Funds (See	Instructions)		
PF, OO			
5. Check if Disclosure of £	f Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6. Citizenship or Place o	f Organization		
Citizen of Russia			
	7. Sole Voting Power		
Number of Shares	8. Shared Voting Power		
Beneficially	91,858,594 <sup>5</sup>		
Owned by Each Reporting	9. Sole Dispositive Power		
Person With:	10. Shared Dispositive Power		
	91,858,594 <sup>5</sup>		
11. Aggregate Amount I	Beneficially Owned by Each Reporting Person		
91,858,594 <sup>5</sup>			
	ate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13. Percent of Class Re	presented by Amount in Row (11)		
46.6% <sup>6</sup>			
14. Type of Reporting P	erson (See Instructions)		
IN			

<sup>&</sup>lt;sup>5</sup> Of the 91,858,594 Common Shares reported, 693,297 Common Shares are held by the Reporting Person and an additional 2,667,501 Common Shares are issuable upon the exercise of warrants to purchase 2,003,001 Common Shares presently exercisable, and the exercise of options to purchase 664,500 Common Shares presently exercisable or which R. Semechkin has the right to exercise within 60 days. 8,000,000 Common Shares are held by X-Master and 5,000,000 Common Shares are issuable upon conversion of 10 shares of Series D Preferred Stock held by X-Master, of which the Reporting Person may be deemed the indirect beneficial owner. 18,536,799 Common Shares are held by A. Semechkin and an additional 42,710,997 Common Shares are issuable upon conversion of 33 shares of Series D Preferred Stock held by A. Semechkin, the exercise of warrants to purchase 23,246,997 Common Shares presently exercisable, and the exercise of options to purchase 2,964,000 Common Shares presently exercisable or which A. Semechkin has the right to exercise within 60 days, of which the Reporting Person may also be deemed the indirect beneficial owner. 14,250,000 Common Shares are issuable upon conversion of 5,000,000 shares of Series G Preferred Stock issued to AR Partners, LLC, of which the Reporting Person may be deemed the indirect beneficial owner.

<sup>&</sup>lt;sup>6</sup> The calculation of the percentage is based on (i) 112,363,815 Common Shares outstanding as of May 3, 2013, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, (ii) 20,000,000 Common Shares outstanding upon a sale by the Issuer on July 24, 2013, as reported by the Issuer in its Current Report on Form 8-K, and (iii) 64,628,498 Common Shares to be issued upon the conversion of 43 shares of Series D Preferred Stock, 5,000,000 shares of Series G Preferred Stock, the exercise of warrants to purchase 25,249,998 Common Shares, and the exercise of options to purchase 3,628,500 Common Shares of the Issuer.

CUSIP No. 05577Y107				
1. Names of Reporting I	Persons.			
AR Partners, LLC				
	e Box if a Member of a Group (See Instructions)			
(a) 🗆	· · · · · · · · · · · · · · · · · · ·			
(b) ⊠				
<ul><li>3. SEC Use Only</li><li>4. Source of Funds (See</li></ul>	Instructions			
4. Source of Funds (See	HISH UCHOILS)			
WC, OO				
£	f Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)			
6. Citizenship or Place o	f Organization			
A Delaware Limited Lia	bility Company			
	7. Sole Voting Power			
Number of Shares	8. Shared Voting Power			
Beneficially	91,858,594 <sup>7</sup>			
Owned by	9. Sole Dispositive Power			
Each Reporting Person With:				
	10. Shared Dispositive Power			
	91,858,594 <sup>7</sup>			
11. Aggregate Amount	11. Aggregate Amount Beneficially Owned by Each Reporting Person			
91,858,594 <sup>7</sup>				
	ate Amount in Row (11) Excludes Certain Shares (See Instructions)			
£  13. Percent of Class Represented by Amount in Row (11)				
13. Percent of Class Re	presented by Amount in Row (11)			
46.6% <sup>8</sup>				
14. Type of Reporting P	erson (See Instructions)			
СО				

<sup>&</sup>lt;sup>7</sup> Of the 91,858,594 Common Shares reported, 14,250,000 Common Shares are issuable upon conversion of 5,000,000 shares of Series G Preferred Stock issued to the Reporting Person. 8,000,000 Common Shares are held by X-Master and 5,000,000 Common Shares are issuable upon conversion of 10 shares of Series D Preferred Stock held by X-Master, of which the Reporting Person may be deemed the indirect beneficial owner. 693,297 Common Shares are held by R. Semechkin, and an additional 2,667,501 Common Shares are issuable upon the exercise of warrants to purchase 2,003,001 Common Shares presently exercisable, and the exercise of options to purchase 664,500 Common Shares presently exercisable or which R. Semechkin has the right to exercise within 60 days, of which the Reporting Person may also be deemed the indirect beneficial owner. An additional 18,536,799 Common Shares are held by A. Semechkin and 42,710,997 Common Shares are issuable upon conversion of 33 shares of Series D Preferred Stock held by A. Semechkin, the exercise of warrants to purchase 23,246,997 Common Shares presently exercisable, and the exercise of options to purchase 2,964,000 Common Shares presently exercisable or which A. Semechkin has the right to exercise within 60 days, of which the Reporting Person may be deemed the indirect beneficial owner.

<sup>&</sup>lt;sup>8</sup> The calculation of the percentage is based on (i) 112,363,815 Common Shares outstanding as of May 3, 2013, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, (ii) 20,000,000 Common Shares outstanding upon a sale by the Issuer on July 24, 2013, as reported by the Issuer in its Current Report on Form 8-K, and (iii) 64,628,498 Common Shares to be issued upon the conversion of 43 shares of Series D Preferred Stock, 5,000,000 shares of Series G Preferred Stock, the exercise of warrants to purchase 25,249,998 Common Shares, and the exercise of options to purchase 3,628,500 Common Shares of the Issuer.

#### Amendment No. 9 to Schedule 13D

This Schedule 13D represents Amendment No. 9 to Schedule 13D ("Amendment") amending and supplementing the Schedule 13D filed with the Securities and Exchange Commission on January 9, 2009, as amended by Amendment No. 1 to Schedule 13D dated January 22, 2009, Amendment No. 2 to Schedule 13D dated March 16, 2009, Amendment No. 3 to Schedule 13D dated June 30, 2009, Amendment No. 4 to Schedule 13D dated September 30, 2009, Amendment No. 5 to Schedule 13D dated October 13, 2009, and Amendment No. 6 to Schedule 13D dated January 18, 2011 by and on behalf of X-Master, Inc. ("X-Master"), Andrey Semechkin ("A. Semechkin"), and Ruslan Semechkin ("R. Semechkin"), and Amendment No. 7 to Schedule 13D dated March 13, 2012 and Amendment No. 8 to Schedule 13D dated January 29, 2013 by and on behalf of X-Master, A. Semechkin, R. Semechkin, and AR Partners, LLC ("AR Partners") (the "Schedule 13D"). AR Partners, X-Master, A. Semechkin, and R. Semechkin are each a "Reporting Person" and collectively, the "Reporting Persons". Unless otherwise stated herein, all capitalized terms used in this Amendment have the same meanings as those set forth in the Schedule 13D.

### ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

Item 5 is hereby amended and restated in its entirety as follows:

(a) As of July 24, 2013, X-Master, by virtue of its beneficial ownership of the Group Shares, beneficially owned the equivalent of 91,858,594 Common Shares. The Group Shares represent approximately 46.6% of the total number of shares of Common Shares outstanding as of July 24, 2013 (plus the 64,628,498 Common Shares which would be outstanding upon the conversion of the Series D and Series G Preferred Stock, exercise of warrants, and exercise of stock options and assuming that no other shares of preferred stock, warrants, or stock options held by others have been previously, or are simultaneously, converted to Common Shares).

As of July 24, 2013, A. Semechkin, by virtue of his beneficial ownership of the Group Shares, beneficially owned the equivalent of 91,858,594 Common Shares. The Group Shares represent approximately 46.6% of the total number of shares of Common Shares outstanding as of July 24, 2013 (plus the 64,628,498 Common Shares which would be outstanding upon the conversion of the Series D and Series G Preferred Stock, exercise of warrants, and exercise of stock options and assuming that no other shares of preferred stock, warrants, or stock options held by others have been previously, or are simultaneously, converted to Common Shares).

As of July 24, 2013, R. Semechkin, by virtue of his beneficial ownership of the Group Shares, beneficially owned the equivalent of 91,858,594 Common Shares. The Group Shares represent approximately 46.6% of the total number of shares of Common Shares outstanding as of July 24, 2013 (plus the 64,628,498 Common Shares which would be outstanding upon the conversion of the Series D and Series G Preferred Stock, exercise of warrants, and exercise of stock options and assuming that no other shares of preferred stock, warrants, or stock options held by others have been previously, or are simultaneously, converted to Common Shares).

As of July 24, 2013, AR Partners, by virtue of its beneficial ownership of the Group Shares, beneficially owned the equivalent of 91,858,594 Common Shares. The Group Shares represent approximately 46.6% of the total number of shares of Common Shares outstanding as of July 24, 2013 (plus the 64,628,498 Common Shares which would be outstanding upon the conversion of the Series D and Series G Preferred Stock, exercise of warrants, and exercise of stock options and assuming that no other shares of preferred stock, warrants, or stock options held by others have been previously, or are simultaneously, converted to Common Shares).

- (b) Number of shares as to which X-Master has:
- i) Sole power to vote or to direct the vote: 0
- (ii) Shared power to vote or to direct the vote: 91,858,594
- (iii) Sole power to dispose or to direct the disposition of: 0
- (iv) Shared power to dispose or to direct the disposition of: 91,858,594

Number of shares as to which A. Semechkin has:

- (i) Sole power to vote or to direct the vote: 0
- (ii) Shared power to vote or to direct the vote: 91,858,594
- (iii) Sole power to dispose or to direct the disposition of: 0
- (iv) Shared power to dispose or to direct the disposition of: 91,858,594

Number of shares as to which R. Semechkin has:

- (i) Sole power to vote or to direct the vote: 0
- (ii) Shared power to vote or to direct the vote: 91,858,594
- (iii) Sole power to dispose or to direct the disposition of: 0
- (iv) Shared power to dispose or to direct the disposition of: 91,858,594

Number of shares as to which AR Partners has:

- (i) Sole power to vote or to direct the vote: 0
- (ii) Shared power to vote or to direct the vote: 91,858,594
- (iii) Sole power to dispose or to direct the disposition of: 0
- (iv) Shared power to dispose or to direct the disposition of: 91,858,594
- (c) On July 24, 2013, A. Semechkin purchased 5,998,999 Common Shares at a price of \$0.15 per share, for a total purchase price of \$899,849.85, and was issued a Series A Warrant to purchase 5,998,999 Common Shares at an exercise price of \$0.15 per share, which is presently exercisable and expires on July 24, 2018, and a Series B Warrant to purchase 5,998,999 Common Shares and 5,998,999 Series A Warrants at an initial exercise price of \$0.15 per share, subject to adjustment, which is presently exercisable and expires on October 23, 2013. The purchase was made pursuant to a certain Subscription Agreement dated July 24, 2013.

On July 24, 2013, R. Semechkin purchased 667,667 Common Shares at a price of \$0.15 per share, for a total purchase price of \$100,150.05, and was issued a Series A Warrant to purchase 667,667 Common Shares at an exercise price of \$0.15 per share, which is presently exercisable and expires on July 24, 2018, and a Series B Warrant to purchase 667,667 Common Shares and 667,667 Series A Warrants at an initial exercise price of \$0.15 per share, subject to adjustment, which is presently exercisable and expires on October 23, 2013. The purchase was made pursuant to a certain Subscription Agreement dated July 24, 2013.

- (d) Not applicable.
- (e) Not applicable.

## ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

Exhibit 1:	Agreement of Joint Filing, dated August 5, 2013, by and among X-Master, Inc., AR Partners, LLC, Andrey Semechkin, and Ruslan Semechkin.
Exhibit 2:	Power of Attorney, dated November 19, 2008, relating to X-Master, Inc. (incorporated by reference to Exhibit 24 of the Reporting Persons' statement on Form 4 with respect to International Stem Cell Corporation, filed on January 2, 2009).
Exhibit 3:	Power of Attorney, dated November 19, 2008, relating to Andrey Semechkin (incorporated by reference to Exhibit 24 of the Reporting Persons' statement on Form 4 with respect to International Stem Cell Corporation, filed on January 2, 2009).
Exhibit 4:	Power of Attorney, dated November 19, 2008, relating to Ruslan Semechkin (incorporated by reference to Exhibit 24 of the Reporting Persons' statement on Form 4 with respect to International Stem Cell Corporation, filed on January 2, 2009).
Exhibit 5:	Power of Attorney, dated March 8, 2012, relating to AR Partners, LLC (incorporated by reference to Exhibit 24 of the Reporting Persons' statement on Form 3 with respect to International Stem Cell Corporation, filed on March 12, 2012).
Exhibit 6:	Form of Series A Warrant (incorporated by reference to Exhibit 4.7 of International Stem Cell Corporation's Current Report on Form 8-K, filed on July 19, 2013).
Exhibit 7:	Form of Series B Warrant (incorporated by reference to Exhibit 4.8 of International Stem Cell Corporation's Current Report on Form 8-K, filed on July 19, 2013).
Exhibit 8:	Form of Subscription Agreement (incorporated by reference to Exhibit 10.1 of International Stem Cell Corporation's Current Report on Form 8-K, filed on July 19, 2013).

[Signature page follows]

## **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 5, 2013 X-Master, Inc.

By: /s/ Michael B. Tule

Name: Michael B. Tule Title: Attorney in fact

Andrey Semechkin

By: <u>/s/ Michael B. Tule</u> Name: Michael B. Tule Title: Attorney in fact

Ruslan Semechkin

By: <u>/s/ Michael B. Tule</u> Name: Michael B. Tule Title: Attorney in fact

AR Partners, LLC

By: /s/ Michael B. Tule Name: Michael B. Tule Title: Attorney in fact

Signature page to AMENDMENT NO. 9 TO SCHEDULE 13D - CUSIP Number 05577Y107

#### AGREEMENT OF JOINT FILING

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of common stock, \$0.001 par value, of International Stem Cell Corporation, a Delaware corporation. The undersigned hereby further agree that this statement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

Dated: August 5, 2013 X-Master, Inc.

By: /s/ Michael B. Tule

Name: Michael B. Tule Title: Attorney in fact

Andrey Semechkin

By: <u>/s/ Michael B. Tule</u> Name: Michael B. Tule Title: Attorney in fact

Ruslan Semechkin

By: /s/ Michael B. Tule Name: Michael B. Tule Title: Attorney in fact

AR Partners, LLC

By: /s/ Michael B. Tule Name: Michael B. Tule Title: Attorney in fact